Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLCJanuary 29th 2021
January 29, 2021 - The combination of pembrolizumab plus concurrent chemoradiation therapy showed antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer, regardless of PD-L1 status or tumor histology.
Pembrolizumab/Lanreotide Combo Confers Antitumor Activity in GEP-NETsJanuary 15th 2021
January 15, 2021 - Pembrolizumab plus lanreotide elicited a stable disease rate of 39% in patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to findings from the phase 1b/2 PLANET study.
Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple MyelomaDecember 5th 2020
December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.
Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial CarcinomaSeptember 20th 2020
Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.
Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPCMay 31st 2020
Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.